View on market: Stay Cautious, be with quality business:

Stocks were volatile in Asia on Wednesday amid a sharp selloff in technology shares and worries that Federal Reserve tightening will plunge the US into recession. The dollar and Treasury yields were steady. Shares in Japan fell and South Korea’s were little changed, while Australian shares rose. US futures advanced afer a weak close in Wall Street, with the Nasdaq 100 down more than 2% after Snap Inc.’s earnings. The Singapore-traded SGX Nifty, an early barometer of India’s benchmark Nifty 50, rose nearly 0.3% to 16,156.60 points as of 6:50 am. Elsewhere, West Texas Intermediate crude rose 0.6% to $110.40 a barrel. Bitcoin hovered around $30,000.

Economic Calendar:

  • INR: FX Reserve on 27thMay
  • INR: GDP Quartely on 31st May 2022.
  • USD: CB Consumer confidence 31st May, 2022.
  • USD: ADP Non Payroll Job Data 1st June, 2022.

Earnings Today: Bharat Petroleum Corporation, Coal India, National Aluminium Company, NHPC, MM Forgings, Apollo Hospitals Enterprises, Interglobe Aviation, Max Healthcare Institute, Torrent Pharmaceuticals, Bata India, Ashoka Buildcon, Fortis Healthcare, Easy Trip Planners, Deepak Fertilizers, Kolte-Patil Developers, Religare Enterprises, Whirlpool of India.

Q4Fy22 Earning:

Adani Ports and Special Economic Zone Q4 FY22 (Consolidated, YoY) Revenue up 6.47% at Rs 3,845.03 crore Vs Rs 3,607.9 crore (Bloomberg estimate: Rs 4,186.7 crore) EBITDA fell 19.57% at Rs 1,858.8 crore Vs Rs 2,310.96 crore (Bloomberg estimate: Rs 2,780.7 crore) EBITDA margin 48.34% Vs 64.05% (Bloomberg estimate: 66.41%) Net profit fell 20.5% at Rs 1,024 crore.

Grasim Industries Q4 FY22 (Standalone, YoY) Revenue up 45.12% at Rs 6,376.9 crore Vs Rs 4,394.25 crore (Bloomberg Estimate: Rs 6,402.4 crore) EBITDA fell 7.13% at Rs 753.09 crore Vs Rs 810.89 crore (Bloomberg Estimate: Rs 903.8 crore) EBITDA margin 11.81% Vs 18.45% (Bloomberg Estimate: 14.11%) Net profit up 122.42% at Rs 1,068.03 crore.

Minda Industries Q4 FY22 (Consolidated, YoY) Revenue up 8% at Rs 2,415.08 crore Vs Rs 2,238.27 crore (Bloomberg estimate: Rs 2,345.2 crore) EBITDA fell 8.65% at Rs 275.50 crore Vs Rs 301.59 crore (Bloomberg estimate: Rs 246.8 crore) EBITDA margin 11.41% Vs 13.47% (Bloomberg estimate: 10.52%) Net profit up 2.9% at Rs 144.37 crore

Dalmia Bharat Sugar and Industries: Q4 FY22 (Consolidated, YoY) Revenue up 75.2% at Rs 856 crore Vs Rs 488.6 crore EBITDA up 2.81% at Rs 130.80 crore Vs Rs 127.23 crore EBITDA margin 15.28% Vs 26.04% Net profit up 7.21% at Rs 55.6 crore Vs Rs 51.86 crore

RITES Q4 FY22 (Consolidated, QoQ) Revenue fell 1.18% at Rs 766.02 crore Vs Rs 775.2 crore EBITDA up 4.41% at Rs 204.47 crore Vs Rs 195.83 crore EBITDA margin 26.7% Vs 25.26% Net profit fell 1.05% at Rs 142.36 crore Vs Rs 143.87 crore

Strides Pharma Science Q4 FY22 (Consolidated, YoY) Revenue down 5% at Rs 866 crore Vs Rs 908 crore (Bloomberg estimate: Rs 826 crore) EBITDA down 74% to Rs 42 crore from Rs 159 crore (Bloomberg estimate: Rs 25 crore Profit) EBITDA margins at 4.8% Vs 17.5% (Bloomberg estimate: 3%) Net profit down 37% to Rs 29 crore.

Brokerage Radar:

JEFFERIES ON GRASIM: Buy, TP Rs 1845 Sluggish 4Q, EBITDA down 7% YoY/18% QoQ on weak VSF profits Highlight for 4Q- doubling paint Capex Finer details like capex constituents, strategy & pace of rampup are missing, which would drive uncertainty in near term.

CITI ON SAIL: Buy, TP cut to Rs 90 from Rs 155 4Q Slightly Ahead; Buy Post the Correction, Potential China Policy Should benefit from import duty removal on coking coal, likely to offset by 15% export duty on steel Cut FY23/24 EBITDA by 56%/47%

International Markets:

U.S & Europe:

Particulars       24th  May    Chg Chg(%)
Nasdaq 11,264.45 -270.83     -2.35
Dow 31928.62 48.38       0.15
FTSE 7,484.35 -29.09 -0.39
CAC 6,253.14 -105.6 -1.66
DAX 13,919.75 -255.65 1.8
Dow Fut.* 32016.50        89.9       0.28

Asian markets:

Particulars    25th May    Chg. Chg(%)
SGX Nifty 16,151.50 37.5 0.23
Nikkei 26,713.08 -35.06 -0.13
Straits Times 3,197.45 2.41 0.08
Hang Seng 20,082.39 -29.71 -0.15
Shanghai 3,076.62 5.69 0.19

ADR Watch:

Particulars     24th May Chg. Chg.(%)
Dr Reddy 56.48 1.41 2.56
HDFC Bank 54.25 0.61 1.14
ICICI Bank 18.33 -0.12 -0.65
Infosys 18.4 -0.49 -2.59
Tata Motor 27.26 -0.12 -0.44
Wipro 5.89 -0.15 -2.48

Commodities & Currency:

Particulars Current Price Chg(%)
USD/INR 77.58 0.09
Brent 111.88 1.09
Gold 1858.59   -0.35
Silver 21.98   -0.30


Particulars 24th May                           23rd May
FIIs -2393.45 -1951.17 
DIIs 1948.49 1445.39

News Update

Eveready Industries: The open offer to acquire 1.88 crore shares representing 26% stake, will begin on June 3 and close on June 16. The offer price is set at Rs 320 per share.

Dr Reddy’s Laboratories: The company along with US based Senores Pharmaceuticals launched Ketorolac Tromethamine Tablet, a therapeutic generic equivalent of the reference listed drug Toradol Tablets.

Titagarh Wagons: The company has bagged its largest order to supply 24,177 wagons from the Indian Railways valued at Rs 7,800 crore. Tts total order book now stands at Rs 10,645 crore.

SIS: The company will acquire 49.99% stake in its subsidiary company Terminix SIS India for Rs 77.5 lakhs. After the acquisition, SIS will fully own the subsidiary.

  Source: Moneycontrol, Livemint,, Bloomberg, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL